{"id":"NCT03795922","sponsor":"Medy-Tox","briefTitle":"MT10109L in the Treatment of Glabellar Lines","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-24","primaryCompletion":"2020-03-13","completion":"2021-01-25","firstPosted":"2019-01-08","resultsPosted":"2023-06-27","lastUpdate":"2023-07-27"},"enrollment":234,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Glabellar Lines"],"interventions":[{"type":"DRUG","name":"MT10109L","otherNames":["NivobotulinumtoxinA"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MT10109L","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the safety and efficacy of MT10109L in the treatment of glabellar lines (GL) in participants with moderate to severe GL.","primaryOutcome":{"measure":"The Percentage of Participants With a â‰¥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND PARTICIPANT Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 30","timeFrame":"Day 30","effectByArm":[{"arm":"Placebo/MT10109L","deltaMin":0,"sd":null},{"arm":"MT10109L/MT10109L","deltaMin":71,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":12},"locations":{"siteCount":15,"countries":["United States","Belgium","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":80},"commonTop":["Headache","Injection site pain"]}}